ライフサイエンスコーパス: leukopenia

1 the suppression of hematopoiesis (anemia and leukopenia).

2 he causal role of the mutant receptor in the leukopenia.

3 mbers of HSCs and committed progenitors; and leukopenia.

4 ty of GM-CSF to reverse chemotherapy-induced leukopenia.

5 ors are used to reverse chemotherapy-induced leukopenia.

6 cer in a mouse model of chemotherapy-induced leukopenia.

7 e neutropenia, thrombocytopenia, anemia, and leukopenia.

8 ounced rescue of radiation-induced anemia or leukopenia.

9 nicity, treatment with immunomodulators, and leukopenia.

10 a new mutant strain, HLB368, with hereditary leukopenia.

11 All grade 4 toxicities were neutropenia or leukopenia.

12 rades 3 and 4 hepatotoxicity and neutropenia/leukopenia.

13 inducing only transient thrombocytopenia and leukopenia.

14 a corresponding increase in antigenemia and leukopenia.

15 illness included tachycardia, tachypnea, and leukopenia.

16 ausea or vomiting, diarrhea, stomatitis, and leukopenia.

17 A virus (IAV) results in a severe transient leukopenia.

18 e being intense fever, thrombocytopenia, and leukopenia.

19 had to be performed in 3 of 13 patients for leukopenia.

20 included a transient loss of body weight and leukopenia.

21 dache, and thrombocytopenia, with or without leukopenia.

22 Six of 20 patients had grade 3 leukopenia.

23 arrhea with hypotension, abdominal pain, and leukopenia.

24 reated patients with bacterial infection had leukopenia.

25 fever, hepatic dysfunction, and progressive leukopenia.

26 ic extramedullary hematopoiesis, anemia, and leukopenia.

27 ith 76% of courses resulting in grade 3 or 4 leukopenia.

28 , thrombocytopenia, anemia, lymphopenia, and leukopenia.

29 oped vascular leakage, thrombocytopenia, and leukopenia.

30 clovir was tolerated without side effects or leukopenia.

31 syndrome, viral infections, and progressive leukopenia.

32 s of thiopurine metabolites, which can cause leukopenia.

33 ions, can be complicated by life-threatening leukopenia.

34 lactate dehydrogenase production, and severe leukopenia.

35 thrombocytopenia (3%), neutropenia (2%), and leukopenia (1%).

36 3) among all cohorts were neutropenia (16%), leukopenia (11%), anemia (9%), and diarrhea (7%).

37 e 3 adverse events were neutropenia (24.5%), leukopenia (14.3%), and thrombocytopenia (12.2%).

38 31 (26%) patients experiencing grade 3 to 4 leukopenia; 15 of 31 patients (48%) experienced grade 3

39 he most common grade 3-4 adverse events were leukopenia (16 [43%] of 37 patients), neutropenia (15 [4

40 3 adverse events included neutropenia (39%), leukopenia (16%), anemia (14%), and diarrhea (13%); the

41 enia (47%), neutropenia (32%), anemia (27%), leukopenia (16%), fatigue (11%), and hyponatremia (10%).

42 notable complications were infections (17%), leukopenia (18%), cardiovascular events (13%), and malig

43 were mucositis (49%), dermatitis (21%), and leukopenia (18%).

44 oxicities were as follows: neutropenia, 64%; leukopenia, 18%; fatigue, 5%; peripheral neuropathy, 5%;

45 e most frequently reported (7%), followed by leukopenia (2%).

46 ion, 20 patients (4.6%) developed persistent leukopenia, 2 patients (0.5%) were diagnosed as having p

47 lib group vs. 0.9% in the placebo group) and leukopenia (21.0% vs. 0.6%); the rates of discontinuatio

48 enia (67%), neutropenia (36%), anemia (28%), leukopenia (22%), and fatigue (11%).

49 (32%), neutropenia (27%), anemia (23%), and leukopenia (23%) reported.

50 utropenia (43%), thrombocytopenia (36%), and leukopenia (23%).

51 Grade 3 toxicities were leukopenia (24%), infection (22%), peripheral neuropathy

52 ts were neutropenia (78%), anemia (28%), and leukopenia (24%).

53 mbocytopenia (13% v 29%), anemia (7% v 15%), leukopenia (26% v 25%), and neuropathy (1% v 5%).

54 han grade 2 toxicities were neutropenia 35%, leukopenia 28%, and metabolic 28%.

55 was mucositis (17%); the only grade 4 AE was leukopenia (3%).

56 included fatigue (22%), infection (9%), and leukopenia (3%).

57 42 patients, seven with grade 3/4 toxicity), leukopenia (33 patients, nine with grade 3/4 toxicity),

58 In group 1, neutropenia (50%) and leukopenia (35%) necessitated dose reductions for 50% of

59 >/=3 toxicities included neutropenia (70%), leukopenia (36%), and lymphopenia (20%).

60 oxicity was primarily hematologic, including leukopenia (46%), thrombocytopenia (13%), and anemia (28

61 r grade 3 toxicities were neutropenia (52%), leukopenia (48%), gastrointestinal (24%), neurologic (18

62 The predominant grade 3 to 4 toxicities were leukopenia (49%), granulocytopenia (55%), and thrombocyt

63 ing more than once included neutropenia (8), leukopenia (5), and lymphopenia (2).

64 st common grades 3 and 4 toxicities included leukopenia (50%), thrombocytopenia (23%), and esophagiti

65 e events included neutropenia (n=107 [43%]), leukopenia (53 [21%]), and anaemia (26 [10%]).

66 to 4 adverse events were neutropenia (63%), leukopenia (54%), anemia (35%), thrombocytopenia (33%),

67 in the chemoradiotherapy-surgery group were leukopenia (6%) and neutropenia (2%); the most common ma

68 (11%), diarrhea (8%), lymphopenia (8%), and leukopenia (6%).

69 The combination produced more grade 3 to 4 leukopenia (62% v 40%), thrombocytopenia (14% v 2%), ane

70 /R+ patients, there was a lower incidence of leukopenia (67% vs. 82%, P=0.039) and trend toward less

71 e 3 or 4 adverse events were mucositis (9%), leukopenia (7%), hyperglycemia (7%), somnolence (6%), th

72 st common toxicities were neutropenia (96%), leukopenia (84%), thrombocytopenia (82%), anemia (74%),

73 eutropenia (199/689 [29%] vs 164/690 [24%]), leukopenia (99/689 [14%] vs 77/690 [11%]), and febrile n

74 Influenza-MRSA was associated with increased leukopenia, acute lung injury, vasopressor use, extracor

75 Leukopenia after kidney transplant increased the risk of

76 end points were the incidence of stomatitis, leukopenia, alopecia, diarrhea, nausea, and vomiting, re

77 le sex, treatment with immunomodulators, and leukopenia also influenced the risk of pneumonia.

78 erved acute hematologic toxicity (5 cases of leukopenia and 2 of thrombocytopenia, all grade 1 or 2)

79 ion between mycophenolate-related anemia and leukopenia and 2724 single nucleotide polymorphisms (SNP

80 worse in our 5-FU-treated patients, profound leukopenia and a need for unplanned hospitalization were

81 while the latter peak was attenuated only by leukopenia and augmented in the accelerated form of this

82 il was associated with a higher incidence of leukopenia and diarrhea, often leading to discontinuatio

83 There were significantly more leukopenia and gastrointestinal adverse events in the MM

84 Leukopenia and gastrointestinal side effects were the mo

85 icant adverse events occurred, although mild leukopenia and increases in aminotransferase activity we

86 hAAT significantly reduced infection-induced leukopenia and liver, pancreas, and lung injury, and it

87 Nonsurvivors were immunosuppressed with leukopenia and markedly reduced tumor necrosis factor-al

88 xicities were hematologic; and acute grade 4 leukopenia and neutropenia occurred in 30.2% and 34.0% o

89 late-onset CMV infections and side effects (leukopenia and neutropenia) than the preemptive strategy

90 atients in the standard arm had grade 3 to 4 leukopenia and neutropenia, but there were more instance

91 ngenital disorder that causes severe chronic leukopenia and neutropenia.

92 They had significant leukopenia and reduced delayed-type hypersensitivity res

93 toms of systemic lupus erythematosus such as leukopenia and renal insufficiency.

94 Younger patients experienced less leukopenia and stomatitis, but more frequent nausea/vomi

95 The incidences of perioperative leukopenia and thrombocytopenia were lower in the outpat

96 ls expressing Delta4 initially suffered from leukopenia and thrombocytopenia.

97 ache, and laboratory abnormalities including leukopenia and thrombocytopenia.

98 g factor (G-CSF) is used clinically to treat leukopenia and to enforce hematopoietic stem cell (HSC)

99 t myelosuppression of grade 3 or 4 in 15.3% (leukopenia) and 7.6% (thrombocytopenia) of applied cycle

100 eukopenia (eight patients had > or = grade 4 leukopenia) and anemia.

101 Four patients experienced grade 2 or 3 leukopenia, and 2 had grade 4 lymphopenia.

102 , aches and pains, positive tourniquet test, leukopenia, and any dengue warning sign; undifferentiate

103 er, fatigue, diarrhea, thrombocytopenia, and leukopenia, and both had been bitten by ticks 5 to 7 day

104 lude flu-like symptoms with fever, diarrhea, leukopenia, and elevated liver enzymes.

105 we assessed Medicare claims for neutropenia, leukopenia, and GCSF use, respectively.

106 Neutropenia, leukopenia, and hypotension occurred more frequently in

107 rombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransferase level

108 ersible elevations in hepatic transaminases, leukopenia, and lymphopenia.

109 related grade 3 or 4 toxicities were anemia, leukopenia, and neutropenia (19% each); lymphopenia (14%

110 , hypotonia and sometimes with polycythemia, leukopenia, and neutropenia.

111 rse effects, such as nephrotoxicity, anemia, leukopenia, and new-onset diabetes after transplantation

112 Mice additionally presented anemia, leukopenia, and splenomegaly.

113 Disseminated infection, leukopenia, and the height of the serum galactomannan in

114 Anemia, neutropenia, leukopenia, and thrombcytopenia were 11%, 32%, 52%, and

115 He was hospitalized with fever, confusion, leukopenia, and thrombocytopenia and developed multiorga

116 For 177Lu-EDTMP, anemia, leukopenia, and thrombocytopenia were nonserious (grade

117 For 153Sm-EDTMP, anemia, leukopenia, and thrombocytopenia were nonserious (grade

118 ntolerance, aminotransferase level increase, leukopenia, and thrombocytopenia.

119 d in Missouri that is associated with fever, leukopenia, and thrombocytopenia.

120 r patients with thrombocytopenia, three with leukopenia, and two with anemia.

121 ity indicators, such as cardiac hypertrophy, leukopenia, and weight and hair loss were not detected w

122 tory abnormalities were common (lymphopenia, leukopenia, anemia, 98% each; neutropenia, 93%; and thro

123 Leukopenia, anemia, and allograft nephrotoxicity were ad

124 opoietic cells leads to bone marrow aplasia, leukopenia, anemia, and early lethality.

125 Grade 3-4 neutropenia, leukopenia, anemia, and thrombocytopenia occurred in a s

126 yalgias, chills, and varying combinations of leukopenia, anemia, and thrombocytopenia.

127 nt-emergent adverse events were neutropenia, leukopenia, anemia, thrombocytopenia, and fatigue.

128 Thrombocytopenia and leukopenia are not infrequent occurrences with SRL treat

129 Mycophenolate-related anemia and leukopenia are well-known toxicities after transplantati

130 though hyperlipidemia, neutropenia, fatigue, leukopenia, arthralgia, and diarrhea were more frequent

131 tion, ATMIN-deficient mice developed chronic leukopenia as a result of high levels of apoptosis in B

132 ith enhanced responses to Cxcl12 and exhibit leukopenia as reported in patients.

133 ts to the occurrence of thrombocytopenia and leukopenia, as well as the severity and the time- and co

134 n high-risk RTR, with a reduced incidence of leukopenia associated with the low-dose regimen and no d

135 one of the SNPs were associated with time to leukopenia at a false discovery rate (FDR) of 20%.

136 p a syndrome of severe thrombocytosis-anemia-leukopenia because of significant increases in megakaryo

137 el, GM-CSF reversed cyclophosphamide-induced leukopenia but also promoted breast cancer and prostate

138 ounts than those of European descent (ethnic leukopenia), but whether this impacts negatively on HIV-

139 There was also significantly more leukopenia, but a greater percentage of T-regulatory cel

140 ytic ehrlichiosis (HGE) developed anemia and leukopenia, but by day 24, they returned to normal value

141 benefits of this growth factor in reversing leukopenia caused by treatment with chemotherapy.

142 (cytokine storm) and loss of T lymphocytes (leukopenia) characterize the most aggressive presentatio

143 he persistence, of both thrombocytopenia and leukopenia correlated significantly with SRL trough conc

144 ter adjustment for age, sex, smoking status, leukopenia, corticosteroid use, and diabetes mellitus.

145 Reversible leukopenia (decline in white blood cell count to <3.0 x

146 nd only Grade 1 thrombocytopenia and Grade 2 leukopenia developed after the second injection, both re

147 ); neutropenia (n = 7); fatigue (n = 4); and leukopenia, diarrhea, and pain (n = 3 each).

148 ost common grade 3 and 4 adverse events were leukopenia (eight [32%]) and neutropenic infections (fiv

149 Major toxicities of therapy were leukopenia (eight patients had > or = grade 4 leukopenia

150 bed association of this genotype with ethnic leukopenia extends to HIV-infected African Americans (AA

151 toxicities were anemia, acne-like skin rash, leukopenia, fatigue and malaise, and nausea and vomiting

152 se of economic importance that causes severe leukopenia, fever and haemorrhagic disease in domesticat

153 ties from IL-2 were mainly thrombocytopenia, leukopenia, fever, and fluid retention.

154 ia, anemia, diarrhea, nausea, rigors/chills, leukopenia, fever, and transaminase elevation.

155 lgia, rash, haemorrhagic manifestations, and leukopenia; fever and at least two of nausea or vomiting

156 were hematologic, including neutropenia and leukopenia followed by neuropathy, myalgia, nausea, fati

157 s having EC-MPS withheld/discontinued due to leukopenia, gastrointestinal symptoms, and infection wer

158 milar in both arms, except for grades 3 to 4 leukopenia (GD, 78%; CD, 66%; P = .025) and transfusions

159 ntensification regimen consisted of grade IV leukopenia, grade IV thrombocytopenia, and febrile neutr

160 CAF produced significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as w

161 The most common toxicities were anemia, leukopenia/granulocytopenia, malaise/fatigue, nausea/vom

162 Leukopenia (>/= grade 3) occurred in 10% of chemotherapy

163 d in patients with anemia, thrombocytopenia, leukopenia, higher blast count, symptoms, large splenome

164 Less prominent reactions included leukopenia, hypertriglyceridemia, and hypercalcemia.

165 4 toxicities occurring in any cycle included leukopenia, hypophosphatemia, asthenia, anemia, and hype

166 toxicity, such as anemia in 22% of patients, leukopenia in 13%, lymphocytopenia in 24%, and thrombocy

167 (11.3%) and 29 administrations (4.6%), with leukopenia in 2.7% and thrombocytopenia in 1.7%.

168 Anemia occurred in 87 (9.5%) subjects and leukopenia in 224 (22.9%).

169 openia both occurring in 41% of patients and leukopenia in 23%.

170 (grade 3 and 4) included neutropenia in 42%, leukopenia in 25%, anemia in 15%, and constitutional in

171 Thrombocytopenia was observed in 70%, leukopenia in 59%; lymphopenia in 45%; and elevated leve

172 a was reported in 87 cycles (31%), grade 3-4 leukopenia in 77 (28%), and grade 3-4 thrombocytopenia i

173 ic circulatory shock, hyperlactacidemia, and leukopenia in a dose-related fashion.

174 cogenetic determinant for thiopurine-induced leukopenia in diverse populations.

175 tive analysis of timing, degree, and type of leukopenia in four groups of patients: cases (n=20); con

176 We induced leukopenia in guinea pigs with vinblastine (0.7 mg/kg, i

177 Mutations in CXCR4 cause severe leukopenia in myelokathexis or WHIM syndrome.

178 mong the elderly (age >70 years), except for leukopenia in one study.

179 e rendered neutropenic develop a generalized leukopenia in response to these three infections.

180 strongly associated with thiopurine-induced leukopenia in subjects with inflammatory bowel disease o

181 Lethality was associated with more severe leukopenia in transgenic versus control mice.

182 were available for four patients, revealing leukopenia in two, lymphopenia in one, and thrombocytope

183 luding neutropenia (in 85% of the patients), leukopenia (in 58%), anemia (in 45%), and thrombocytopen

184 , respectively, for thiopurine-induced early leukopenia (in comparison to 12.1% and 97.6% for TPMT va

185 ildren with recurrent infections, congenital leukopenia including neutropenia, B and T cell lymphopen

186 , but immunologic stress conditions inducing leukopenia increase the demand for peripheral blood cell

187 IV but was the most active at preventing the leukopenia induced by TNF alpha in mice, providing more

188 t treatment with N-acetylcysteine, or severe leukopenia induced by vinblastine.

189 cytopenia, prolonged bleeding times, anemia, leukopenia, infertility, cardiomyopathy, and shortened l

190 This leukopenia is associated with genetic variation in TPMT

191 Asians, the incidence of thiopurine-induced leukopenia is higher in Asians than in individuals of Eu

192 use of severe adverse drug reactions (ADRs); leukopenia is one of the most serious ADRs.

193 32.6%, P = 0.049) and a higher incidence of leukopenia less than 2000/mm (28.6% vs 9.8%; P = 0.001)

194 IV-infected subjects, we show that, although leukopenia (< 4000 WBC/mm(3) during infection) was assoc

195 -dependent thrombocytopenia (<61%, p < .05), leukopenia (<60%, p < .05), and mortality rate (50% at 5

196 were compatible with laboratory findings of leukopenia, lymphopenia, and thrombocytopenia.

197 zziness, myalgias, abdominal pain, anorexia, leukopenia, lymphopenia, thrombocytopenia, or elevated l

198 veloping CMV disease, the rate and extent of leukopenia may be reduced.

199 Leukopenia may confound population studies that estimate

200 rombocytopenia (n = 5), neutropenia (n = 2), leukopenia (n = 1), and transient ischemic attack (n = 1

201 es simplex stomatitis associated with severe leukopenia (n = 1), asymptomatic leukopenia (n = 2), nau

202 pancreatitis (n = 1), and pneumonia without leukopenia (n = 1).

203 with severe leukopenia (n = 1), asymptomatic leukopenia (n = 2), nausea/ diarrhea (n = 2), thinning o

204 sed erythematous rash (n=334)-fever (n=333), leukopenia (n=217), and headache (n=203) were most commo

205 nd ulcers (n=2)] or bone marrow suppressive [leukopenia (n=9), anemia (n=6), and thrombocytopenia (n=

206 de 3 and 4 adverse events were hyperlipemia, leukopenia, nausea, vomiting, pneumonia, dyspnea, anemia

207 d a significantly lower rate of grade 3 to 4 leukopenia, neutropenia, and stomatitis and a lower rate

208 ost common toxicities were myelosuppression (leukopenia, neutropenia, and thrombocytopenia) and eleva

209 The most frequent grade 3/4 toxicities were leukopenia, neutropenia, anemia, thrombocytopenia, and n

210 Grade 4 leukopenia, neutropenia, febrile neutropenia, and enceph

211 dverse events were hand-foot syndrome (29%), leukopenia/neutropenia (24%), and fatigue (19%).

212 1 (56%) developed grade 3 or 4 toxicity with leukopenia/neutropenia, nausea/vomiting, and metabolic t

213 Grade 3 or 4 toxicities included leukopenia/neutropenia, thrombocytopenia, elevation of a

214 ent-related grade 3 to 4 toxicities included leukopenia/neutropenia, transient elevation of aminotran

215 Bacterial loads, MODS, leukopenia, neutrophil infiltration, immune cell activat

216 Only five episodes of grade III leukopenia occurred (14% of patients, 2% of doses), and

217 Grade III to IV leukopenia occurred in 32% of patients; 63% received pla

218 Grade 3/4 leukopenia occurred in 53% of patients, but only six pat

219 Grade 3 or 4 leukopenia occurred in 73% of patients in the ST arm and

220 For regimen B, severe leukopenia occurred in 86% to 100%, with febrile neutrop

221 Greater incidence of leukopenia occurred in group II at month 1 only (P=0.002

222 3 or 4 hematologic toxicity was common, with leukopenia occurring in 41.2% (grade 3, 29%; grade 4, 12

223 tive antineoplastic agent; however, grade IV leukopenia occurs in the large majority of patients trea

224 gly associated with thiopurine-induced early leukopenia (odds ratio (OR) = 35.6; P(combined) = 4.88 x

225 also 11% more likely than men to experience leukopenia of common toxicity criteria grade >/= 1, (70%

226 atients on carboplatin plus paclitaxel), and leukopenia (one patient on carboplatin plus paclitaxel).

227 maintenance was low after R-CHOP (grade 3-4 leukopenia or infection < 5%) but more prominent in pati

228 (P = 0.003), tachypnea (OR 1.9, P = 0.001), leukopenia or leukocytosis (total white blood cell count

229 Safety review of leukopenia or thrombocytopenia did not differ.

230 Leukopenia or thrombocytopenia was seen in 82% of patien

231 patients who had fever accompanied by marked leukopenia or thrombocytopenia were serologically confir

232 Leukopenia (OR = 1.97; 95% CI, 1.39-2.79; P = .0001; Q =

233 , bacteremia (OR = 2.8; 95% CI, 2.3 to 3.6), leukopenia (OR = 2.5, 95% CI, 1.6 to 3.7), and multiloba

234 Each patient had thrombocytopenia, leukopenia, or both.

235 ity (>29.6 GBq) was associated with relevant leukopenia (P < 0.001).

236 leukopenia was 67% compared with 4% without leukopenia (p < 0.01).

237 PM 5-FU concentrations correlated with worse leukopenia (P = .04) and severity of mucositis (P = .04)

238 associated with the incidence and degree of leukopenia (P = 0.02) and thrombocytopenia (P = 0.03).

239 Grade 3 and 4 leukopenia (P =.002) and neutropenia (P =.008) occurred

240 ug-related G3 and G4 events included anemia, leukopenia, pancytopenia, nausea, hyperbilirubinemia, hy

241 ed cause of reversible refractory anemia and leukopenia, particularly neutropenia, often misdiagnosed

242 ing was targeted in group II to avoid severe leukopenia previously seen with alemtuzumab.

243 Cyclophosphamide-mediated leukopenia reduced the size of the bacterial challenge d

244 provide a partial explanation of why ethnic leukopenia remains benign in HIV-infected AAs, despite i

245 Leukopenia, renal toxicity, peripheral neurotoxicity, an

246 ts experienced anemia, thrombocytopenia, and leukopenia, respectively.

247 ts experienced anemia, thrombocytopenia, and leukopenia, respectively.

248 neutropenia (13 [30%]), anaemia (11 [25%]), leukopenia (seven [16%]), febrile neutropenia (seven [16

249 c fevers (VHFs), including thrombocytopenia, leukopenia, skin and internal organ hemorrhages, high vi

250 3 to 4 neutropenia, febrile neutropenia, and leukopenia than etoposide-carboplatin; grade 3 to 4 thro

251 ious adverse events, but more frequent early leukopenia than induction with Atgam.

252 gimen experienced more severe stomatitis and leukopenia than men.

253 y acquire clinical symptoms of lupus such as leukopenia, thrombocytopenia and renal dysfunction.

254 system, and its use has resulted in cases of leukopenia, thrombocytopenia, and aplastic anemia.

255 H7N9 patients had similar patterns of leukopenia, thrombocytopenia, and elevated alanine amino

256 ehrlichioses with fever, headache, myalgias, leukopenia, thrombocytopenia, and elevated liver enzyme

257 l findings include fever, headache, myalgia, leukopenia, thrombocytopenia, and hepatic inflammatory i

258 CsA dose delivered (34.6 mg/kg) were anemia, leukopenia, thrombocytopenia, and hypertension.

259 Significant leukopenia, thrombocytopenia, and peripheral neuropathy

260 Leukopenia, thrombocytopenia, gastrointestinal symptoms,

261 ab maintenance after R-FC, in whom grade 3-4 leukopenia (up to 40%) and infections were frequent (up

262 iated with thrombocytosis, thrombocytopenia, leukopenia, venous thromboembolism, hyposplenism, and Ig

263 while the overall incidence of grade 3 or 4 leukopenia was 21.5% of patients.

264 Mortality associated with leukopenia was 67% compared with 4% without leukopenia (

265 The incidence of nephrotic syndrome and leukopenia was also lower in cluster 1 than in cluster 2

266 The incidence of grade 4 leukopenia was higher in patients with prior pelvic radi

267 Severe or life-threatening leukopenia was more common in the HU group (24%) than in

268 Leukopenia was more common with Thymoglobulin than Atgam

269 Grade 3 leukopenia was observed in 1 patient.

270 % of patients, 2% of doses), and no grade IV leukopenia was produced.

271 Leukopenia was seen in 20% of patients, and allograft fu

272 DLT (grade 3 stomatitis, diarrhea, leukopenia) was observed in cohorts 1, 2, and 4.

273 Thrombocytopenia and leukopenia were also observed.

274 ore frequent with mTORi-CNI and diarrhea and leukopenia were more frequent with MMF/MPA-CNI.

275 Hypothermia, bradycardic hypotension, and leukopenia were most severe and prolonged in BDL + LPS r

276 received regimen A induction, grades 3 and 4 leukopenia were observed in 50% to 65%, with one toxicit

277 bronchitis, tooth infection, stomatitis, and leukopenia were reported.

278 therapy pretransplant and the occurrence of leukopenia were risk factors (OR per year, 1.192 [95% CI

279 Thrombocytopenia and leukopenia were the dose-limiting toxicities.

280 Neutropenia and leukopenia were the most common grade 3 and 4 toxicities

281 Hypertriglyceridemia and leukopenia were the most frequent adverse events, occurr

282 Stomatitis, diarrhea, and leukopenia were the predominant chemotherapy toxicities.

283 , and metabolic toxicity, as well as grade 4 leukopenia, were significantly more frequent in arm I.

284 The most common adverse effect was leukopenia, which occurred in 40% of patients.

285 The principal toxicity was leukopenia, which occurred with rapid onset and brief du

286 uated by decomplementation, neutropenia, and leukopenia, while the latter peak was attenuated only by

287 oglobin<10 gm/dL or hematocrit<30%) or first leukopenia (white blood cell [WBC] count <3000 cells/mm)

288 (platelet count <150x10(3) cell/mm3) and/or leukopenia (white blood cell count <5,000/mm3).

289 s included grade 2 transaminitis and grade 4 leukopenia with a grade 3 infection.

290 possible mechanisms behind this IAV-induced leukopenia with emphasis on the potential induction of a

291 a weak tendency to increased neutropenia and leukopenia with higher ganciclovir exposure.

292 Leukopenia with neutropenia developed in each patient, a

293 tients presenting with refractory anemia and leukopenia with or without associated neurologic deficit

294 vere cytopenia was observed in all patients; leukopenia (with median leukocyte count of 1400/mm3) was

295 The major toxicity was leukopenia, with 61% of patients who had grade 3 or 4.

296 generally mild: only 25 patients experienced leukopenia, with a median WBC count of 2,900 (range, 800

297 Infection was defined as leukocytosis or leukopenia, with a positive culture requiring either med

298 nificant difference occurred in incidence of leukopenia, with higher rates for AC-T-H versus AC-T (od

299 d mice exhibited anemia, thrombocytosis, and leukopenia, with pronounced pan-lymphopenia as demonstra

300 y utilized for CMV prophylaxis but can cause leukopenia, with risk compounded by the use of myelosupp